Deka Bank Deutsche Girozentrale Dynavax Technologies Corp Transaction History

Deka Bank Deutsche Girozentrale

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$12.64 - $14.99 $28,566 - $33,877	2,260 New	2,260 $33,000
Q2 2020 Aug 04, 2020	SELL	$2.94 - $9.1 $35,280 - $109,200	-12,000 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$3.46 - $6.93 $899,600 - $1.8 Million	-260,000 Reduced 95.59%	12,000 $72,000
Q3 2019 Nov 14, 2019	SELL	$2.69 - $4.85 $699,400 - $1.26 Million	-260,000 Reduced 48.87%	272,000 $963,000
Q2 2019 Aug 01, 2019	BUY	$3.65 - $7.89 $474,500 - $1.03 Million	130,000 Added 32.34%	532,000 $2.05 Million
Q1 2019 May 10, 2019	SELL	$7.08 - $12.09 $188,328 - $321,594	-26,600 Reduced 6.21%	402,000 $5.45 Million
Q4 2018 Feb 12, 2019	BUY	$8.14 - $13.28 $216,524 - $353,248	26,600 Added 6.62%	428,600 $3.72 Million
Q3 2018 Nov 09, 2018	BUY	$11.85 - $16.0 $758,400 - $1.02 Million	64,000 Added 18.93%	402,000 $0
Q2 2018 Aug 14, 2018	BUY	$15.15 - $20.75 $666,600 - $913,000	44,000 Added 14.97%	338,000 $5.17 Million
Q1 2018 May 03, 2018	BUY	$14.65 - $19.9 $4.01 Million - $5.45 Million	274,000 Added 1370.0%	294,000 $5.78 Million
Q3 2017 Nov 06, 2017	BUY	$15.2 - $21.5 $304,000 - $430,000	20,000	20,000 $333,000

275

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.63B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.